Download PDF
Z Gastroenterol 2013; 51(4): 384-389
DOI: 10.1055/s-0033-1335042
Übersicht
© Georg Thieme Verlag KG Stuttgart · New York

Mukosaschutz durch Phosphatidylcholin als neues therapeutisches Prinzip bei der Colitis ulcerosa

Mucosal Protection by Phosphatidylcholine as New Therapeutic Concept in Ulcerative Colitis
W. Stremmel
Further Information

Publication History

19 October 2012

30 January 2013

Publication Date:
12 April 2013 (online)

Also available at
    Permissions and Reprints

Zusammenfassung

Die Schleimschicht auf der Kolonmukosa stellt die erste Barriere gegen eine Invasion kommensaler Bakterien im Stuhl dar. Ein essenzieller Bestandteil des intestinalen Mucus ist Phosphatidylcholin (PC), welches mehr als 90 % der Phospholipide im Mucus ausmacht und deshalb als selektive Anreicherung von PC in diesem Kompartiment angesehen wird. Phosphatidylcholin ist in lamellaren Strukturen, ähnlich wie das Surfactant der Lunge, angeordnet und konstituiert somit eine hydrophobe Schicht auf der Oberfläche des wässrigen Mucusgels, um so vor der Invasion von Bakterien aus dem intestinalen Lumen zu schützen. Bei Colitis ulcerosa (UC) ist der PC-Gehalt des Mucus um 70 % vermindert unabhängig davon, ob die Schleimhaut entzündet ist oder nicht. Somit ist der verminderte PC-Gehalt im Mucus eine intrinsische primäre pathogenetische Voraussetzung zur Invasion von Bakterien und Auslösung von Entzündung. Da PC vornehmlich von der ilealen Mukosa sezerniert wird, kann man vermuten, dass dieses Phospholipid nach distal ins Kolon wandert und auf seinem Weg entlang der Kolonwand bis hin zum Rektum kontinuierlich ausgedünnt wird mit der geringsten PC-Konzentration im Rektum. Dies erklärt den Start der klinischen Manifestation der Colitis ulcerosa als Prokititis und seine Ausbreitung nach proximal bis zum Zökalpol entsprechend dem Grad der Verminderung des PC-Gehaltes im Schleim. Wenn dieses fehlende Mucus-Phosphatidylcholin bei Colitis ulcerosa mithilfe einer oralen, verzögert freigesetzten PC-Präparation wieder zugeführt wird, kann der Mangel ausgeglichen werden. In 3 randomisierten doppelblinden klinischen Studien konnte gezeigt werden, dass die Entzündung bei Colitis ulcerosa deutlich vermindert wird, ja sogar in Remission überführt wird. Diese Daten beweisen die essenzielle Rolle der Mucus-PC-Konzentration zum Schutz gegen Entzündung im Kolon. Daraus kann ein erfolgreiches neues Therapieprinzip mit oraler Applikation von verzögert im distalen Ileum freigesetztem Phosphatidylcholin entwickelt werden.

Abstract

The colonic mucus serves a first barrier towards invasion of commensal bacteria in stool. One essential component of intestinal mucus is phosphatidylcholine (PC) which represents more than 90 % of the phospholipids in mucus indicative for a selective transport of PC into this compartment. It is arranged in lamellar structures as surfactant-like particles which provide a hydrophobic surface on top of the hydrated mucus gel to prevent invasion of bacteria from the intestinal lumen. In ulcerative colitis (UC) the mucus PC content is reduced by 70 % irrespective of the state of inflammation. Thus, it could represent an intrinsic primary pathogenetic condition predisposing to bacterial invasion and precipitation of inflammation. Since PC was shown to be mainly secreted by the ileal mucosa from where it is assumed to move distally to the colon, the PC content along the colonic wall towards the rectum gradually thins out with lowest PC content in the rectum. It explains the start of the clinical manifestation of UC in the rectum and expansion from there to the upper parts of the colon. When the lacking mucus PC in the UC was supplemented by an oral, delayed released PC preparation, it was shown in three clinical trials that the inflammation improved and even resolved. The data indicate the essential role of the mucus phosphatidylcholine content for protection against inflammation in colon. This can be the basis for the development of an innovative therapy for ulcerative colitis using orally available delayed released phosphatidylcholine.

Schlüsselwörter

Phosphatidylcholin - Lecithin - Mucus - Mukosabarriere - Colitis ulcerosa

Key words

phosphatidylcholine - lecithin - mucus - mucosal barrier - ulcerative colitis
 

  • Literatur

  • 1 Podolsky D. Inflammatory bowel disease. N Engl J Med 2002; 347: 417-429
    CrossrefPubMedGoogle Scholar
  • 2 Backhed F, Ley RE, Sonnenburg JL et al. Host-bacterial mutualism in the human intestine. Science 2005; 307: 1915-1920
    CrossrefPubMedGoogle Scholar
  • 3 Gerseman M, Wehkamp J, Stange EF. Innate immune dysfunction in inflammatory bowel disease. Intern Med J 2012; 271 (5) 421-428
    CrossrefPubMedGoogle Scholar
  • 4 Becker T, Loch G, Beyer M et al. FOXO-dependent regulation of innate immune homeostasis. Nature 2010; 463: 369-373
    CrossrefPubMedGoogle Scholar
  • 5 Atuma C, Strugala V, Allen A et al. The adherent gastrointestinal mucus gel layer: thickness and physical state in vivo . Am J Physiol Gastrointest Liver Physiol 2001; 280: G922-G929
    PubMedGoogle Scholar
  • 6 Shirazi T, Longman RJ, Corfield AP et al. Mucins and inflammatory bowel disease. Postgrad Med J 2000; 76: 473-478
    CrossrefPubMedGoogle Scholar
  • 7 Johannson MEV, Phillipson M, Petersson J et al. The inner of the two Muc2 mucin-dependent mucus layers in colon is devoid of bacteria. Proc Natl Acad Sci U S A 2008; 105: 15064-15069
    CrossrefPubMedGoogle Scholar
  • 8 Matsuo K, Ota H, Akamatsu T et al. Histochemistry of the surface mucous gel layer of the human colon. Gut 1997; 40: 782-789
    CrossrefPubMedGoogle Scholar
  • 9 Hicks AM, DeLong CJ, Thomas MJ et al. Unique molecular signatures of glycerophospholipid species in different rat tissues analyzed by tandem mass spectrometry. Biochim Biophys Acta 2006; 1761: 1022-1029
    CrossrefPubMedGoogle Scholar
  • 10 Hills BA. Surface-active phospholipid: a Pandora's box of clinical applications. Part II. Barrier and lubricating properties. Intern Med J 2002; 32 (5 – 6) 242-251
    CrossrefPubMedGoogle Scholar
  • 11 Lichtenberger LM. The hydrophobic barrier properties of gastrointestinal mucus. Annu Rev Physiol 1995; 57: 565-583
    Google Scholar
  • 12 Willumeit R, Schuster A, Iliev P et al. Phospholipids as implant coatings. J Mater Sci Mater Med 2007; 18 (02) 367-80
    CrossrefPubMedGoogle Scholar
  • 13 Ehehalt R, Jochims C, Lehmann WD et al. Evidence of luminal phosphatidylcholine secretion in rat ileum. Biochim Biophys Acta 2004; 1682: 63-71
    CrossrefPubMedGoogle Scholar
  • 14 Engle MJ, Grove ML, Becich MJ et al. Appearance of surfactant-like particles in apical medium of Caco-2 cells may occur via tight junctions. Am J Physiol 1995; 268: C1401-C1413
    PubMedGoogle Scholar
  • 15 Ehehalt R, Wagenblast J, Erben G et al. Phosphatidylcholine and lysophosphatidylcholine in intestinal mucus of ulcerative colitis patients. A quantitative approach by nanoElectrospray-tandem mass spectrometry. Scand J Gastroenterol 2004; 39 (08) 737-742
    CrossrefPubMedGoogle Scholar
  • 16 Braun A, Treede I, Gotthardt D et al. Alterations of phospholipid concentration and species composition of the intestinal mucus barrier in ulcerative colitis: a clue to pathogenesis. Inflamm Bowel Dis 2009; 15: 1705-1720
    CrossrefPubMedGoogle Scholar
  • 17 Braun A, Schoenfeld U, Welsch T et al. Reduced hydrophobicity of the colonic mucosal surface in ulcerative colitis as a hint at a physicochemical barrier defect. Int J Colorectal Dis 2011; 26: 898-998
    PubMedGoogle Scholar
  • 18 Meves A, Stremmel C, Gottschalk K et al. The kindling protein family: new members to the club of focal adhesion proteins. Trends Cell Biol 2009; 19: 504-512
    CrossrefPubMedGoogle Scholar
  • 19 Ussar S, Moser M, Widmaier M et al. Loss of Kindlin-1 causes skin atrophy and lethal neonatal intestinal epithelial dysfunction. PLoS Genet 2008; 4: e1000289
    CrossrefPubMedGoogle Scholar
  • 20 Gibson PR, Muir JG. Reinforcing the mucus: a new therapeutic approach for ulcerative colitis?. Gut 2005; 54: 900-903
    CrossrefPubMedGoogle Scholar
  • 21 Nazareth M, Mahadevan U. Phosphatidylcholine in steroid refractory chronic ulcerative colitis – is it all in the mucus?. Ann Intern Med 2007; 147: 603-610
    CrossrefPubMedGoogle Scholar
  • 22 Karner M, Ehehalt R, Stremmel W. Retarded release phosphatidylcholine: A new therapeutic option for ulcerative colitis. In: Dignass A, Rachmilewitz D, Stange EF, et al.eds. Immunoregulation in Inflammatory Bowel Diseases – Current Understanding and Innovation. Heidelberg, Dordrecht, New York: Springer; 2007: 161-170
    CrossrefGoogle Scholar
  • 23 Anes E, Kühnel MP, Bos E et al. Selected lipids activate phagosome actin assembly and maturation resulting in killing of pathogenic mycobacteria. Nat Cell Biol 2003; 5 (09) 793-802 Epub 2003 Aug 24
    CrossrefPubMedGoogle Scholar
  • 24 Treede I, Braun A, Jeliaskova P et al. TNF-alpha-induced up-regulation of pro-inflammatory cytokines is reduced by phosphatidylcholine in intestinal epithelial cells. BMC Gastroenterol 2009; 13 (09) 53
    PubMedGoogle Scholar
  • 25 Are AF, Galkin VE, Pospelova TV et al. The p65/RelA subunit of NF-kappaB interacts with actin-containing structures. Exp Cell Res 2000; 256 (02) 533-44
    CrossrefPubMedGoogle Scholar
  • 26 Stremmel W, Merle U, Zahn A et al. Retarded release phosphatidylcholine benefits patients with chronic active ulcerative colitis. Gut 2005; 54: 966-971
    CrossrefPubMedGoogle Scholar
  • 27 Stremmel W, Braun A, Hanemann A et al. Delayed Release Phosphatidylcholine in Chronic-active Ulcerative Colitis: A Randomized, Double-blinded, Dose Finding Study. J Clin Gastroenterol 2010; 44 (05) e101-e107
    PubMedGoogle Scholar
  • 28 Stremmel W, Ehehalt R, Autschbach F et al. Phosphatidylcholine for steroid–refractory chronic ulcerative colitis: a randomized trial. Ann Intern Med 2007; 147 (09) 603-610
    CrossrefPubMedGoogle Scholar
  • 29 Karner M, Kocjan A, Stein J et al. Modified Release Phosphatidylcholine „LT-02“ in Active Ulcerative Colitis: a Randomized, Placebo-Controlled Multicentre Study. Gastroenterology 2012; 142 (05) (Suppl. 01) 211
    PubMedGoogle Scholar
  • 30 Prantera C, Lochs H, Grimaldi M et al. Retic Study Group (Rafaximin-Eir-Treatment in Crohn’s Disease). Rifaximin-Extended Intestinal Release Induces Remission in Patients With Moderatley Active Crohn’s Disease. Gastroenterology 2012; 142 (03) 473-481
    CrossrefPubMedGoogle Scholar
  • 31 Travis SP, Stange EF, Lemann M et al. European evidence-based consensus on the management of ulcerative colitis: current management. J Crohns Colitis 2008; 2 (01) 24-62
    PubMedGoogle Scholar